AtherosclerosisPub Date : 2026-11-09DOI: 10.1016/j.atherosclerosis.2026.121953
Ernesto Martín-Núñez, Mattie Garaikoetxea, Alba Sádaba, Carolina Tiraplegui, Amaya Fernández de Celis, Blanca Otegui, Susana San Ildefonso-García, Miriam Goñi-Olóriz, Virginia Álvarez, Adela Navarro, Rafael Sádaba, Natalia López-Andrés
{"title":"Molecular signatures associated with reduced renal function in aortic regurgitation and aortic stenosis.","authors":"Ernesto Martín-Núñez, Mattie Garaikoetxea, Alba Sádaba, Carolina Tiraplegui, Amaya Fernández de Celis, Blanca Otegui, Susana San Ildefonso-García, Miriam Goñi-Olóriz, Virginia Álvarez, Adela Navarro, Rafael Sádaba, Natalia López-Andrés","doi":"10.1016/j.atherosclerosis.2026.121953","DOIUrl":"https://doi.org/10.1016/j.atherosclerosis.2026.121953","url":null,"abstract":"<p><strong>Background and aims: </strong>Chronic kidney disease (CKD) accelerates aortic valve (AV) disease, yet the molecular pathways linking declining renal function to aortic regurgitation (AR) and aortic stenosis (AS) remain poorly defined. We aimed to characterize AV phenotype-specific molecular signatures associated with reduced renal function.</p><p><strong>Methods: </strong>We performed an observational cross-sectional study using targeted proteomic profiling (Olink) in human AV from patients with AR or AS, stratified by renal function (eGFR≥60 vs < 60 mL/min/1.73 m<sup>2</sup>). Pathway enrichment analyses were performed using exploratory candidate proteins. Candidate molecular signatures were subsequently examined in independent cohorts (AR: n = 215; AS: n = 325) across renal function categories using histology, immunohistochemistry, ELISA, and qPCR.</p><p><strong>Results: </strong>Reduced renal function was associated with distinct molecular patterns in AR and AS. In AR, exploratory proteomic profiling suggested enrichment of neutrophil degranulation, chemotaxis/adhesion and thrombo-inflammatory signaling pathways. Tissue characterization showed progressive extracellular matrix remodeling, collagen maturation, increased neutrophil markers (NGAL, MPO) and upregulation of pro-inflammatory (IL6, IL-8, IL-32, IL-33, CCL-2, TNF-α, RANTES), pro-adhesive (ICAM-1) and pro-thrombotic mediators (PAI-1) across renal function categories. In AS, exploratory proteomics suggested matrix disassembly and osteogenic signatures, while tissue characterization showed greater valvular calcification (BMP-2, -4, -9), collagen degradation (COL1, MMP-1, -3, TIMP-1) and inflammatory infiltration with declining renal function. Shared candidate proteins showed opposite regulation in AR and AS.</p><p><strong>Conclusions: </strong>Reduced renal function is associated with distinct, phenotype-specific patterns of AV remodeling-predominantly thrombo-inflammatory in AR and osteogenic-matrix-disruptive in AS- indicating heterogeneous molecular responses across the two major forms of aortic valve disease.</p>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"423 ","pages":"121953"},"PeriodicalIF":7.1,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AtherosclerosisPub Date : 2026-11-05DOI: 10.1016/j.atherosclerosis.2026.121951
Janneke W C M Mulder, Jing Pang, Marianne Klevmoen, Leonieke W Kranenburg, Annette M H Galema-Boers, Kjetil Retterstøl, Eric Boersma, Gerald F Watts, Kirsten B Holven, Jeanine E Roeters van Lennep
{"title":"Family planning, pregnancy and breastfeeding care in familial hypercholesterolaemia (Taking ACTion to Improve Care of coupleS in FH (TACTICS)): a mixed methods study.","authors":"Janneke W C M Mulder, Jing Pang, Marianne Klevmoen, Leonieke W Kranenburg, Annette M H Galema-Boers, Kjetil Retterstøl, Eric Boersma, Gerald F Watts, Kirsten B Holven, Jeanine E Roeters van Lennep","doi":"10.1016/j.atherosclerosis.2026.121951","DOIUrl":"https://doi.org/10.1016/j.atherosclerosis.2026.121951","url":null,"abstract":"<p><strong>Background and aims: </strong>Familial hypercholesterolemia (FH) is a common genetic condition causing premature atherosclerotic cardiovascular disease (ASCVD), and family planning, pregnancy and breastfeeding are important phases of care. We investigated awareness, knowledge and practices regarding these phases among individuals with FH, partners, and healthcare professionals (HCPs).</p><p><strong>Methods: </strong>An exploratory mixed-methods study was conducted in the Netherlands, Norway and Australia. Interviews with individuals with heterozygous FH (HeFH) explored experiences of care related to family planning and were analysed following reflexive thematic analysis. Partners completed an anonymous survey on the impact of FH on their relationship. HCPs were surveyed on family planning and pregnancy practices.</p><p><strong>Results: </strong>Twenty-six individuals with HeFH (62% women, median age 37 [IQR 33-42] years, 15% ASCVD) were interviewed. Experiences varied widely, with women reporting the greatest impact, particularly concerning pregnancy, breastfeeding and treatment interruption. Among 175 partners of subjects with FH (55% men, median age 48 [37-60] years, 82% with children), 25% reported a past and/or current negative impact of FH on their relationship. FH influenced family planning in 11% of couples, with a higher proportion among those aged 30-39 years (35%). 107 HCPs (median practice duration 21 [12-30] years, median FH-caseload 50 [15-128]) completed the survey. Most (89%) discussed family planning, mainly concerning inheritance (94%) and preconception medication advice (91%). Most HCPs recommended statin discontinuation during conception, pregnancy and breastfeeding; 46% recommended breastfeeding duration similar to that for general population.</p><p><strong>Conclusions: </strong>Substantial heterogeneity exists in counselling practices, highlighting the need for standardised care pathways to improve guidance and support individuals with FH and their partners in family planning, pregnancy and breastfeeding.</p>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"423 ","pages":"121951"},"PeriodicalIF":7.1,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AtherosclerosisPub Date : 2026-11-04DOI: 10.1016/j.atherosclerosis.2026.121950
Amara Synøve Øgaard Uduma, Elise Sverre, John Munkhaugen, Kjetil Retterstøl, Kirsten B Holven, Nils Tore Vethe
{"title":"Sex-specific clinical and psychosocial characteristics among individuals with familial hypercholesterolemia reporting side-effects of lipid-lowering therapy.","authors":"Amara Synøve Øgaard Uduma, Elise Sverre, John Munkhaugen, Kjetil Retterstøl, Kirsten B Holven, Nils Tore Vethe","doi":"10.1016/j.atherosclerosis.2026.121950","DOIUrl":"https://doi.org/10.1016/j.atherosclerosis.2026.121950","url":null,"abstract":"<p><strong>Background and aims: </strong>Symptoms attributed to lipid-lowering therapy (LLT) may affect adherence. We explored sex-specific clinical and psychosocial characteristics associated with self-perceived side-effects of LLT in individuals with familial hypercholesterolemia (FH).</p><p><strong>Methods: </strong>Adults (N = 2709) with FH, identified through a quality registry, were invited to a cross-sectional study. Participants completed a self-report questionnaire covering side-effects, use of LLT, muscle symptoms, pain treatment and psychosocial factors.</p><p><strong>Results: </strong>Among 613 participants (22.6% response rate), median age was 55 (IQR; 43, 65) years and 56% were women. Forty-five (13%) women and 47 (17%) men reported self-perceived side-effects of LLT. In both sexes, self-perceived side-effects were associated with significantly higher perceived sensitivity to medicines, more concerns about LLT, higher ratings of muscle symptoms and pain intensity, and lower self-rated general health. Among women, those with side-effects were more frequently living alone (38% vs 20%, p = 0.017) and reported more musculoskeletal complaints (62% vs 37%, p = 0.004). Among men, those reporting side-effects had higher median LDL-cholesterol (2.5 vs 2.1, p = 0.032), and higher prevalence of depressive symptoms (30% vs 11%, p = 0.003) and insomnia (60% vs 41%, p = 0.045). Adjustment for age, cardiovascular comorbidity and BMI made only minor changes in the effect estimates in logistic regression analyses.</p><p><strong>Conclusions: </strong>Participants with FH and self-perceived side-effects reported a significant symptom burden and concerns about the use of LLT. Women with side-effects more frequently reported musculoskeletal complaints and living alone, whereas psychological distress and insomnia were more prominent among men reporting side-effects. Individual assessments of sex-specific characteristics may be valuable for improving follow-up.</p>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"423 ","pages":"121950"},"PeriodicalIF":7.1,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AtherosclerosisPub Date : 2026-11-03DOI: 10.1016/j.atherosclerosis.2026.121952
Adriana Koller, Hansi Weissensteiner
{"title":"Mitochondrial DNA in cardiovascular disease.","authors":"Adriana Koller, Hansi Weissensteiner","doi":"10.1016/j.atherosclerosis.2026.121952","DOIUrl":"https://doi.org/10.1016/j.atherosclerosis.2026.121952","url":null,"abstract":"<p><p>Genetic contributions to cardiovascular disease (CVD) are typically examined through nuclear DNA, yet mitochondrial DNA (mtDNA) is increasingly recognized as a critical, often overlooked determinant of cardiovascular risk. Given the heart's reliance on mitochondrial energy production, mitochondrial dysfunction and mtDNA alterations have emerged as important contributors to CVD pathogenesis. This review examines current evidence linking mtDNA variants, including heteroplasmy and deletions, mtDNA copy number (mtDNA-CN) dynamics, and haplogroup background to major CVD phenotypes, with particular emphasis on atherosclerosis, cardiomyopathy, myocardial infarction, stroke, hypertension, and heart failure. We conducted a comprehensive PubMed search, prioritizing human population-based and clinical studies, supplemented by key experimental data informing mechanisms. Evidence is strongest for roles of mtDNA variants and heteroplasmy in cardiomyopathies/heart failure, as well as hypertension by impairing mitochondrial energy production and generating harmful oxidants, creating a continuous cycle of mitochondrial injury with further mtDNA damage, besides additional contributions from mtDNA-CN, large deletions, and mitochondrial haplogroups. Mechanistically, mtDNA abnormalities may promote vascular inflammation, endothelial dysfunction, and altered immune signalling; the inflammatory response is a central pathogenic driver of cardiovascular disease, directly promoting atherosclerotic plaque instability, adverse myocardial remodelling, and the progression of heart failure. We subsequently evaluate the evidence for each CVD phenotype in relation to these mtDNA markers. Lastly, current knowledge gaps, methodological challenges, and future research priorities are discussed to support the integration of mtDNA into cardiovascular research and precision medicine.</p>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"423 ","pages":"121952"},"PeriodicalIF":7.1,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149376995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Relationship of atherosclerotic lesion by optical coherence tomography with cholesterol efflux capacity by immobilized liposome-bound gel beads method","authors":"Tsunehiro Miyakoshi, Yuna Horiuchi, Makoto Araki, Taishi Yonetsu, Mei Watanabe, Takahiro Kameda, Akira Yoshimoto, Naoya Ichimura, Shuji Tohda, Minoru Tozuka, Tetsuo Sasano, Ryunosuke Ohkawa","doi":"10.1016/j.atherosclerosis.2026.120724","DOIUrl":"10.1016/j.atherosclerosis.2026.120724","url":null,"abstract":"<div><h3>Background and aims</h3><div>Cholesterol efflux capacity (CEC) is robust biomarker for atherosclerotic cardiovascular disease (ASCVD). However, cell-based CEC assays require complex procedures that limit clinical use. The immobilized liposome-bound gel beads (ILG) method, a newly developed cell-free CEC assay, demonstrates sufficient performance for clinical application. This study investigated the clinical significance of CEC measured by the ILG method in relation to HDL subclasses and coronary artery plaque characteristics.</div></div><div><h3>Methods</h3><div>We analyzed CEC and HDL parameters, including the ratio of apolipoprotein E (apoE)-HDL-C to HDL-C (%apoE) and HDL<sub>3</sub>-C/HDL<sub>2</sub>-C, in 61 patients who underwent coronary angiography or percutaneous coronary intervention. Coronary artery plaques were assessed by optical coherence tomography (OCT). A large lipid-rich plaque was defined as lipid length >5 mm and lipid arc >180°.</div></div><div><h3>Results</h3><div>CEC correlated positively with HDL-C and %apoE. Among the patients, 26 (42.6%) exhibited large lipid-rich plaques on OCT. Univariable analysis showed that CEC was significantly lower in patients with large lipid-rich plaques compared to those without. While this association did not reach statistical significance after multivariable adjustment (p = 0.109), the addition of CEC to traditional risk factors improved the model's explanatory power (Nagelkerke R<sup>2</sup>: 0.346 to 0.381) and discriminatory ability (AUC: 0.775 to 0.805) for large lipid-rich plaques.</div></div><div><h3>Conclusions</h3><div>CEC measured using the ILG method reflects HDL subclass features and is associated with the burden of lipid-rich coronary artery plaques. These findings suggest the significance of CEC evaluated using the ILG method, supporting its potential for enhanced ASCVD risk assessment and further clinical applications.</div></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"422 ","pages":"Article 120724"},"PeriodicalIF":7.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147653538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AtherosclerosisPub Date : 2026-11-01Epub Date: 2026-09-17DOI: 10.1016/j.atherosclerosis.2026.121904
Stephen J. Nicholls MBBS PhD
{"title":"What does focal coronary imaging tell us about the whole patient?","authors":"Stephen J. Nicholls MBBS PhD","doi":"10.1016/j.atherosclerosis.2026.121904","DOIUrl":"10.1016/j.atherosclerosis.2026.121904","url":null,"abstract":"","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"422 ","pages":"Article 121904"},"PeriodicalIF":7.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149029827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AtherosclerosisPub Date : 2026-11-01Epub Date: 2026-10-09DOI: 10.1016/j.atherosclerosis.2026.121928
Karam Kostner
{"title":"Lp(a) reduction with PCSK9 inhibitors: How does real-world data stack up?","authors":"Karam Kostner","doi":"10.1016/j.atherosclerosis.2026.121928","DOIUrl":"10.1016/j.atherosclerosis.2026.121928","url":null,"abstract":"","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"422 ","pages":"Article 121928"},"PeriodicalIF":7.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AtherosclerosisPub Date : 2026-10-31DOI: 10.1016/j.atherosclerosis.2026.121944
Takahito Doi, Shoaib Afzal, Gorm Boje Jensen, Børge Grønne Nordestgaard
{"title":"Atherosclerotic events and acute pancreatitis incidence across the full range of plasma triglycerides in four large cohorts.","authors":"Takahito Doi, Shoaib Afzal, Gorm Boje Jensen, Børge Grønne Nordestgaard","doi":"10.1016/j.atherosclerosis.2026.121944","DOIUrl":"https://doi.org/10.1016/j.atherosclerosis.2026.121944","url":null,"abstract":"<p><strong>Background and aims: </strong>We tested the hypothesis that triglycerides at most levels are associated with higher incidence of ASCVD than acute pancreatitis.</p><p><strong>Methods: </strong>We examined individuals from the Copenhagen City Heart Study (CCHS) 1976-78 (n = 14,292; a median follow-up of 24 years) and 1991-94 (n = 10,093; 20 years), the Copenhagen General Population Study (CGPS) 2003-15 (n = 107,297; 13 years), the UK Biobank 2006-10 (n = 468,964; 14 years), and nationwide in Denmark 2008-21 (n = 3,415,915; 6 years).</p><p><strong>Results: </strong>The incidence was statistically higher for ASCVD than for acute pancreatitis at any plasma triglycerides up to 30 mmol/L (2657 mg/dL) in all cohorts, while nationwide in Denmark the incidence of acute pancreatitis was nominally higher than that of ASCVD at triglycerides of 50 mmol/L (4429 mg/dL) or higher. In women, age-adjusted incidence rates per 1000 person-years per 1 mmol/L (89 mg/dL) higher plasma triglycerides across all levels were 1.8 (95% confidence interval 1.2-2.3) for ASCVD versus 0.1 (0.02-0.2) for acute pancreatitis in the CCHS 1976-78, 1.9 (1.2-2.5) versus 0.1 (0.01-0.2) in the CCHS 1991-94, 0.9 (0.7-1.0) versus 0.1 (0.1-0.1) in the CGPS, 0.6 (0.6-0.7) versus 0.2 (0.2-0.2) in the UK Biobank, and 0.4 (0.4-0.5) versus 0.05 (0.04-0.05) nationwide in Denmark. Corresponding values in men were 1.5 (1.0-2.0) versus 0.1 (0.1-0.1), 0.9 (0.5-1.3) versus 0.04 (0-0.1), 1.1 (0.9-1.3) versus 0.04 (0-0.08), 1.1 (1.0-1.2) versus 0.1 (0.1-0.1), and 0.6 (0.5-0.6) versus 0.05 (0.05-0.06), respectively.</p><p><strong>Conclusions: </strong>The incidence of ASCVD was statistically higher than that of acute pancreatitis up to triglycerides of 30 mmol/L (2657 mg/dL), while acute pancreatitis was nominally higher than ASCVD at 50 mmol/L (4429 mg/dL) or higher.</p>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"423 ","pages":"121944"},"PeriodicalIF":7.1,"publicationDate":"2026-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149376994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AtherosclerosisPub Date : 2026-10-30DOI: 10.1016/j.atherosclerosis.2026.121941
Teresa Gijón-Conde
{"title":"Non-HDL cholesterol as a lipid control target in severe hypercholesterolemia in primary care: a sex-stratified analysis.","authors":"Teresa Gijón-Conde","doi":"10.1016/j.atherosclerosis.2026.121941","DOIUrl":"https://doi.org/10.1016/j.atherosclerosis.2026.121941","url":null,"abstract":"<p><strong>Background and aims: </strong>Non-HDL cholesterol (non-HDL-C) is recognized as a co-primary lipid target by the 2019 ESC/EAS guidelines, yet its attainment in patients with severe hypercholesterolemia (SH) in primary care remains poorly characterized. We aimed to assess non-HDL-C goal attainment in SH, examine LDL-C/non-HDL-C discordance, and evaluate sex differences in treatment and lipid control.</p><p><strong>Methods: </strong>Cross-sectional, multicenter study using electronic health records from 156,082 adults attending 69 primary care centers in Madrid (2018-2021). SH was defined as total cholesterol ≥300 mg/dL or LDL-C ≥220 mg/dL. Non-HDL-C goal was <100 mg/dL per ESC/EAS 2019. Discordance was defined as LDL-C <70 mg/dL with non-HDL-C ≥100 mg/dL. Sex-stratified multivariable logistic regression identified independent predictors of goal attainment.</p><p><strong>Results: </strong>Of 6071 patients with SH, only 228 (3.8%) achieved non-HDL-C <100 mg/dL. Men received high/very high intensity lipid-lowering therapy (LLT) more often than women (34.1% vs 26.0%; p < 0.001), yet non-HDL-C levels were higher in men across all treatment categories except very high intensity. Among patients with established ASCVD, men achieved the target more often than women at both the <100 mg/dL (13.9% vs 6.1%; p = 0.001) and <85 mg/dL thresholds (7.8% vs 2.6%; p = 0.022). LDL-C/non-HDL-C discordance was identified in 21.3% of patients with LDL-C <70 mg/dL, more frequently in men (31.8% vs 13.8%; p = 0.006), and increased with triglyceride levels. LLT intensity was not independently associated with goal attainment; diabetes, age, obesity, and ASCVD were the main predictors.</p><p><strong>Conclusions: </strong>Non-HDL-C goal attainment is critically low in SH patients in primary care, independently of treatment intensity. Sex disparities were significant, particularly in secondary prevention. Systematic non-HDL-C monitoring via electronic records and greater use of combination LLT are needed.</p>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":" ","pages":"121941"},"PeriodicalIF":7.1,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AtherosclerosisPub Date : 2026-10-09DOI: 10.1016/j.atherosclerosis.2026.121926
Pompilio Faggiano, Giacomo Gamberini, Andrea Faggiano
{"title":"Beyond a single measurement: the role of cumulative LDL-C exposure after percutaneous coronary intervention.","authors":"Pompilio Faggiano, Giacomo Gamberini, Andrea Faggiano","doi":"10.1016/j.atherosclerosis.2026.121926","DOIUrl":"https://doi.org/10.1016/j.atherosclerosis.2026.121926","url":null,"abstract":"","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":" ","pages":"121926"},"PeriodicalIF":7.1,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149222957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}